News
CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings
At the American Society of Clinical Oncologyopens in a new tab or window (ASCO) annual meeting, a poster discussion session on metastatic breast cancer entitled "CDK4/6 Inhibitors: New Populations, Different Settings" was presented by Maryam Lustberg, MD, MPH opens in a new tab or window, the chief of breast oncology at the Yale Cancer Center in New Haven, Connecticut. She discussed the results from three posters -- the LEONARDA-1 studyopens in a new tab or window, the PALOMAGE programopens in a new tab or window, and the AURORA Molecular Screening Initiativeopens in a new tab or window.
Source: MedPage Today